中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (8): 553-558.doi: 10.12144/zgmfskin202508553

• 论著 • 上一篇    下一篇

真实世界中利特昔替尼治疗成人斑秃10例疗效观察

林上清,王志强,许炎竹,王海波,柯玚颖,陈成,曾丽月,姜晓勇   

  1. 厦门大学附属中山医院皮肤科，厦门大学医学院，福建厦门，361004
  • 出版日期:2025-08-15 发布日期:2025-07-31

Efficacy of ritlecitinib in 10 adult with alopecia areata：a real world study

LIN Shangqing, WANG Zhiqiang, XU Yanzhu, WANG Haibo, KE Yangying, CHEN Cheng, ZENG Liyue, JIANG Xiaoyong   

  1. Department of Dermatology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361004, China
  • Online:2025-08-15 Published:2025-07-31

PDF (PC)

23

摘要： 目的：评估真实世界中利特昔替尼治疗成人斑秃的有效性和安全性。方法：回顾性分析2023年12月至2024年12月于我院使用利特昔替尼治疗的10例成人斑秃患者的临床资料，比较治疗前及治疗4、8、12、16周的脱发严重程度评分(SALT)、皮肤病生活质量评分(DLQI)、斑秃症状影响量表评分(AASIS)、睡眠状况自评分(SRSS)的变化，记录治疗过程中的不良反应。结果：与基线相比，治疗后第4、8、12和16周时SALT评分分别下降了1.1%，25.3%，46.5%，63.7%，生活质量改善分别0%，0%，29.2%，68.8%，斑秃相关症状影响改善分别为6.5%，4.7%，41.7%，49.4%，睡眠质量改善0%，7.1%，11.9%，18%。随访期间部分患者出现轻微不良反应，均对症处理后好转。结论：利特昔替尼对成人斑秃具有较好的疗效和安全性，能够显著改善患者的脱发严重程度、生活质量、斑秃相关症状及睡眠质量。

关键词: 利特昔替尼, 成人斑秃, 真实世界

Abstract: Objective: To evaluate the efficacy and safety of ritlecitinib in the treatment of adult alopecia areata in real-world practice. Methods: A retrospective analysis was performed on the clinical data of 10 adult patients with alopecia areata who received ritlecitinib treatment in our hospital from December 2023 to December 2024. Changes in the Severity of Alopecia Tool (SALT) score, Dermatology Life Quality Index (DLQI) score, Alopecia Areata Symptom Impact Scale (AASIS) score, and self-rated sleep status score were compared before treatment and at 4, 8, 12, and 16 weeks after treatment. Adverse reactions during treatment were recorded. Results: Compared with the baseline, the SALT scores at 4, 8, 12, and 16 weeks after treatment decreased by 1.1%, 25.3%, 46.5%, and 63.7% respectively; the improvement in quality of life was 0%, 0%, 29.2%, and 68.8% respectively; the improvement in alopecia areata-related symptom impact was 6.5%, 4.7%, 41.7%, and 49.4% respectively; and the improvement in sleep quality was 0%, 7.1%, 11.9%, and 18% respectively. During the follow-up period, some patients experienced mild adverse reactions, all of which improved after symptomatic treatment. Conclusion: Ritlecitinib has good efficacy and safety in adult alopecia areata, and can significantly improve the severity of hair loss, quality of life, alopecia areata-related symptoms, and sleep quality in patients.

Key words: ritlecitinib, adult alopecia areata, real world